Therefore, it would be informative to test whether the metabolic benefits of dietary interventions and SGLT2 inhibitors against NAFLD are mediated via Hmgcs2 activation. The gene discussed is HMGCS2; the disease is metabolic dysfunction-associated steatotic liver disease.